Eiger BioPharma's Single Dose Of Peginterferon Lambda Cuts Risk Of COVID-19-Related Hospitalizations, Deaths

Vandana Singh
1 min read
0
In this article:

  • Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine.

  • The data exhibited that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events.

  • The primary endpoint was a composite endpoint of COVID-19-related hospitalization or emergency room visits greater than six hours.

  • Secondary endpoints included SARS-CoV-2 viral clearance, all-cause hospitalization, mortality due to COVID-19, days in the hospital and on a ventilator, and adverse events.

  • In the study, 931 patients received peginterferon lambda, and 1,018 received a placebo.

  • The publication detailed results, highlighting a 51% reduction in the risk of hospitalization or emergency room visits (primary endpoint) with peginterferon lambda.

  • Lambda reduced the risk of hospitalization by 42% and COVID-19-related death by 50%

  • Related: Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment.

  • The risk of COVID-19 hospitalization or all-cause death was reduced by 47% in participants receiving peginterferon lambda.

  • In patients receiving treatment within three days of symptom onset, greater treatment effects were observed in the peginterferon lambda group, including a 65% reduction of COVID-19-related hospitalization, 81% risk reduction in all-cause death, and 89% risk reduction among unvaccinated patients.

  • Price Action: EIGR shares are up 39.9% at $2.85 on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Eiger BioPharma's Single Dose Of Peginterferon Lambda Cuts Risk Of COVID-19-Related Hospitalizations, Deaths originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories